Generation of antigen-specific CD4+ T cell lines from naive precursors

The conditions required for sensitizing naive T cells to nominal antigen are poorly understood. In this report we describe an in vitro system for generating antigen-specific CD4⁺ T cells from previously unprimed individuals. Freshly isolated CD4⁺ T cells were cultured with keyhole limpet hemocyanin (KLH), sperm whale myoglobin (SWM), or human immunodeficiency virus (HIV) gp 160, antigens to which most persons have not been sensitized, in the presence of either dendritic cells (DC) or macrophages (MΦ). In short-term (< 8 days) cultures, CD4⁺ T cells or their CD4⁺, CD45RA (naive) subpopulation mounted significant proliferative responses to KLH, SWM, and HIV gp160, but only if the antigens were presented by DC. In contrast, CD4⁺, CD45RO (memory) T cells responded poorly to these antigens, although they responded vigorously to tetanus toxoid, a recall antigen, presented by either DC or MΦ. KLH- and SWM-specific CD4⁺ T cell lines were established from the starting population that had been sensitized in vitro, following repeated stimulation with antigen and MΦ in medium supplemented with interleukin-2 and interleukin-4. Despite the continued presence of these cytokines during T cell expansion, the expanded lines retained their ability to respond to the priming antigen in the absence of exogenous cytokines. When the CD45RA and CD45RO subpopulations were sensitized and expanded separately, the CD45RA cells alone gave rise to antigen-specific T cell lines, while the CD45RO cells proliferated nonspecifically. These results demonstrate that human naive CD4⁺ T cells can be sensitized in vitro to nominal antigens presented by DC and that the sensitized cells can be expanded into long-term lines that retain their antigen specificity.     

白细胞介素-10诱导的大鼠树突状细胞体外免疫功能的研究

目的　研究白细胞介素 10 (IL 10 )诱导的大鼠未成熟树突状细胞 (imDCs)体外诱导免疫耐受的可行性。方法　在经典诱导方案的基础上 ,应用IL 10 ( 10 μg/L)抑制大鼠骨髓来源DCs的成熟 (IL 10组 ,10例 ) ,并设对照组 (IL 4组 ,10例 )。培养期间观察DCs形态 ,检测DCs表型、摄取抗原能力、体外免疫功能及培养上清细胞因子水平。结果　与IL 4组比较 ,IL 10组DCs细胞表面CD80 、CD86及OX6低度表达 ( 2 5 .3 %、42 .4%、3 2 .3 % ) ,吞噬能力较强 ( 81.9) ,刺激同种异体淋巴细胞增殖能力下降 ,该淋巴细胞具有抗原特异性低反应性 ;培养上清中IL 12水平 ( 4 0 6.5pg/L)及初次MLR培养上清IL 2水平 ( 2 45 .4ng/L)均较低 ,差异有非常显著性 (P <0 .0 1)。 结论　IL 10作用的大鼠imDCs具有诱导免疫耐受的应用价值。     

The role of dendritic cells during infection

The skin and the mucosa of the respiratory and gastrointestinal tracts are continuously exposed to microorganisms, but only a limited number of these enter the body and cause disease. To resist microbial infection, the host has developed a multitude of defense mechanisms involving the innate and adaptive immune systems. Dendritic cells (DCs) provide the link between these arms of the immune system. The initiation of an immune response is critically dependent on the activation of DCs, which can discriminate between different classes of microorganisms and elicit tailored antimicrobial immune responses. They have an extraordinary capacity to stimulate naive T cells and initiate primary immune responses. In turn, some pathogens interfere with DC function to block or delay their elimination by the host. Progress in understanding the role of DCs in the host response to microbes is reviewed.     

西罗莫司与未成熟树突状细胞延长小鼠皮肤移植存活时间的协同作用

目的 研究西罗莫司（SRL）对小鼠骨髓源树突状细胞（DC）分化及成熟的影响，观察西罗莫司与未成熟树突状细胞在延长小鼠皮肤移植存活时间中的协同作用。方法 （1）在诱导C57BL／6小鼠骨髓细胞定向分化为DC时加入SRL，通过流式细胞仪检测CD11c、CD86及MHCⅡ类分子表达情况，经脂多糖（LPS）刺激后，再检测各分子表达的变化。（2）通过单向混合淋巴细胞反应（MLR）观察经SRL处理的DC刺激同种异基因小鼠T细胞增殖情况。（3）以C57BL／6小鼠为供者，BALB／c小鼠为受者建立皮肤移植模型。观察皮肤移植前7d经尾静脉注射供者未成熟DC及经胃管连续灌注SRL7d的受者移植皮片存活情况及组织学变化。结果 （1）经SRL处理的DC表面CD11c表达仅有轻度降低，但CD86和MHCⅡ类分子表达明显减少。（2）MLR显示经SRL处理的DC刺激同种异基因小鼠T细胞增殖的能力降低。（3）受者皮肤移植术前联合应用供者未成熟DC和SRL，可减轻移植皮片炎症反应并延长其存活时间。结论 SRL对DC分化的影响不明显，但可抑制DC发育成熟。受者术前应用SRL和未成熟DC可延长皮肤移植的存活时间。     

恶性肿瘤局部淋巴结树突状细胞免疫组化研究

本文采用S-100蛋白为免疫学标记，对34例恶性肿瘤局部淋巴结内树突状细胞进行免疫组化定量研究。结果按S-100蛋白阳性细胞数目多少分为增多（7例）、减少（20例）及正常（7例）3组，统计学分析增多组均值（164.4个/mm^2)明显高于对照组（58.3个/mm^2)；减少组均值（16.5个/mm^2)组显低于对照组；而正常组均值（69.8个/mm^2)与对照组无显著差异。     

高迁移率族蛋白B1对大鼠脾脏树突状细胞表面共刺激分子表达的影响

目的观察高迁移率族蛋白B1(HMGB1)对树突状细胞(dendritic cells,DC)表面共刺激分子表达的影响,并对其机制进行初步探讨。方法分离正常Wistar大鼠脾脏DC后置于96孔培养板(1×10~5/孔),采用HMGB1刺激,观察HMGB1刺激与DC表面共刺激分子CD80、CD86和主要组织相容性复合物(MHC)Ⅱ表达的时间-效应关系及剂量-效应关系。结果HMGB1刺激后,DC表面共刺激分子CD80、CD86和MHCⅡ表达分别于24～72 h明显上调(P＜0．05,0．01),其中以作用48 h后DC表面共刺激分子表达上调尤为显著(P＜0．01)；0．1μg/ml、1μg/ml、10μg/ml的HMGB1刺激均可诱导DC表面共刺激分子CD80、CD86和MHCⅡ表达增强(P＜0．05,0．01),其中HMGB1的浓度在1μg/ml时,大鼠DC表面共刺激分子CD80、CD86和MHCⅡ的表达增强最明显(P＜0．01)。结论HMGB1能诱导DC表面共刺激分子表达增强,HMGB1可能是诱导DC成熟的免疫刺激信号。     

白细胞介素-12基因修饰对树突状细胞表面分子表达及细胞因子分泌的影响

目的 观察白细胞介素(IL)-12基因修饰对树突状细胞(DC)表面分子及细胞因子分泌的影响.方法 采用重组逆转录病毒介导IL-12基因修饰人外周血单个核细胞(PBMC)来源的Dc;ELISA法检测各组DCs和各组T细胞上清中IL-12、IL-10、IFN-γ因子的分泌水平;流式细胞仪(FACS)分析各组DC表面CD83、CD86的表达;MTT法检测DC刺激同源T淋巴细胞增殖的能力;统计学分析比较各组间的差异.结果 IL-12基因修饰使得DC高表达CD83和CD86分子,分泌高水平IL-12及IFN-γ,但对IL-10因子的分泌无明显影响,刺激同源T淋巴细胞增殖明显,诱导激活的T细胞上清中IFN-γ水平显著增高、IL-10分泌水平显著降低.结论 经IL-12基因修饰后的DC表型成熟,分泌IL-12及IFN-γ的能力增强,对IL-10因子的分泌无影响,能抑制T细胞分泌IL-10因子,优化抗原提呈的微环境.     

沉默树突状细胞恒定链以增强其抗肿瘤作用的体外实验研究

目的初步观察用小分子干扰RNA(siRNA)沉默树突状细胞(DCs)恒定链(Ii)后,DCs疫苗的体外抗肿瘤效果。方法从小鼠骨髓分离骨髓前体细胞,细胞经100 ng/ml GM-CSF和100 ng/ml IL-4诱导培养6 d后,转染针对DCs Ii链特异的Ii-siRNA,转染后加用50 ng/ml TNF-α继续诱导细胞成熟48 h,然后分别用Western blot检测沉默效果及CCK-8试剂盒检测DCs刺激同种异体淋巴细胞增殖的能力;此外,DCs共转染Ii-siRNA和小鼠胃癌前体细胞MFC的总RNA后,与同种异体淋巴细胞共培养,通过ELISA检测培养上清IFN-γ/和IL-4的水平,并收集致敏淋巴细胞进行体外杀伤实验。结果Ii-siRNA明显抑制DCs Ii的表达。沉默Ii链能够增强DCs的淋巴细胞增殖能力,并促使淋巴细胞向Th1的方向漂移[IFN-γ:(5107±351)pg/ml,IL-4:(65±13)pg/ml,P＜0．05]。淋巴细胞经共转染Ii-siRNA和MFC RNA的DCs激活后,明显而特异地杀伤靶肿瘤细胞(杀伤百分率: 66．94%±2．75%,P＜0．05)。结论通过siRNA沉默DCs的Ii链可能是一种行之有效的增强抗肿瘤免疫的方法。     

Dendritic cells therapy

Dendritic cells (DC) are potent regulators of the immune system. Today, much research is being done trying to understand how DCs can be harnessed to induce immunity and how we can better exploit their potentials. Here, the present understanding of DC biology, function and use is summarized.     

Dendritic Cells Coinjected with Tumor Cells Treated with an Anticancer Drug to Induce Tumor Rejection

Purpose: We examined whether bone marrow-derived dendritic cells (DCs) could induce antitumor immunity when a chemotherapeutic drug was added. Methods: CT26 (a murine colon cancer cell line syngeneic with BALB/c) and CT26-bearing mice were treated with mitomycin C (MMC) intraperitoneally (i.p.). Next, mice immunized with a coinjection of DCs and MMC-treated CT26 (i.p.) were given an intradermal inoculation of CT26. Finally, CT26-bearing mice were treated with MMC (i.p.) with or without DCs, given peritumorally. Results: Although the inoculated tumor was not rejected in the control mice, CT26 was rejected in 50% of the mice injected with MMC alone. Apoptosis was observed in the MMC-treated CT26 cells in vitro and in vivo. Immunization with DCs and apoptotic CT26 cells, but not with apoptotic CT26 alone, gave protection against tumor challenge in 7 of 13 mice. A significantly higher level of cytotoxic T-cell activity and interferon-γ production was seen in the protected mice. When MMC (i.p.) treatment was followed by peritumoral DC injection in the CT26-bearing mice, remarkable therapeutic effects were observed. Conclusion: DCs can collaborate with chemotherapy-induced apoptotic tumor cells and elicit improved antitumor immunity, probably through the acquisition of tumor-associated antigens from apoptotic tumor cells. Received: January 7, 2002 / Accepted: September 3, 2002 Acknowledgments. We thank Dr. Kazuo Kinoshita for his useful advice on using flow cytometry. This research was partly supported by the Ministry of Education, Culture, Sports, Science and Technology (No. 11671160). Reprint requests to: S. Yamasaki